Book Value per Share: PDS Biotechnology Corporation (PDSB)

Graphic logo of PDS Biotechnology Corp (PDSB)

PDS Biotechnology's optimization of biochemical supply chains, combined with its authority as a leader in T-cell immunity, establishes a resilient business foundation. The IFRS book value per share reflects this potential, with the metric reaching -0.06. The readiness of laboratory capacities for mass drug production promises further growth in the company's capitalization.

PDSB: PDS Biotechnology Net Asset Value per Share 07/04/2022 - 10/26/2026

PDS Biotech - analytical breakdowns and key metrics (PDSB)

- price and consensus price forecast:
Price Chart PDS Biotechnology Corp|PDSB - Analyst Median Target
- market capitalization data:
Market Capitalization PDS Biotechnology Corporation|PDSB - Total Company Value
- book capitalization data:
Net Assets per Single Share PDS Biotechnology|PDSB - Total Stockholders' Equity|Market Value to Book Value Ratio pdsbiotech.com|PDSB - Total Business Assets
- debt and liquidity data:
Total Debt to Capital PDS Biotechnology|PDSB - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity PDS Biotechnology Corp|PDSB - Company Cumulative Debt|Debt to Book Capitalization Ratio PDS Biotechnology Corporation
Fundamental company valuation:PDSB - pdsbiotech.com
Flagship merchandise of PDS Biotechnology Corp

The success of PDS Biotechnology (PDSB) depends on the effectiveness of the Versamune platform and regulatory approvals, rendering its market capitalization sensitive to clinical trial results. The book value per share, calculated as the difference between total assets and liabilities, allows for the tracking of hidden asset impairment risks; therefore, the trend in book value per share serves as an indicator of investor protection against value traps.

Competitor analysis for PDS Biotechnology

Net Assets per Single Share IBRX (ImmunityBio Corp)|IMCR - Net Assets per Share|Janux Therapeutics (JANX) - Book Value per Share|RCUS (arcusbio.com) - Net Assets per Single Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx